Table 2.
Timing | Tumor characteristics | Nerve-sparing | Hormone therapy | |||||
---|---|---|---|---|---|---|---|---|
Pearson r p-value |
Age at RP | Follow-up duration | Age at follow-up | PSA | T-stage | Gleason score | ||
UF | -0.093 0.075 |
-0.091 0.080 |
-0.119 0.023 |
-0.167 0.001 |
-0.139 0.008 |
-0.184 0.001 |
0.096 0.066 |
-0.131 0.017 |
UB | -0.049 0.348 |
-0.079 0.131 |
-0.076 0.145 |
-0.142 0.006 |
-0.163 0.002 |
-0.156 0.004 |
0.117 0.025 |
-0.105 0.055 |
SF |
-0.247 < 0.001 |
-0.214 <0.001 |
-0.298 <0.001 |
-0.111 0.033 |
-0.144 0.006 |
-0.150 0.006 |
0.272 <0.001 |
-0.113 0.039 |
SB | 0.061 0.244 |
0.240 <0.001 |
0.144 0.006 |
0.050 0.338 |
-0.180 <0.001 |
-0.033 0.552 |
0.162 0.002 |
-0.143 0.009 |
Significant correlations (p ≤ 0.05) are in bold.
[UF: urinary function; UB: urinary bother; SF: sexual function; SB: sexual bother; RP: radical prostatectomy]